AXSM

Company Overview — What Does Axsome Therapeutics, Inc. Do?

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. Axsome Therapeutics, Inc. (AXSM) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Herriott Tabuteau and employs approximately 380 people, headquartered in NEW YORK, New York. With a market capitalization of $8.8B, AXSM is one of the notable companies in the Healthcare sector.

Axsome Therapeutics, Inc. (AXSM) Stock Rating — Reduce (April 2026)

As of April 2026, Axsome Therapeutics, Inc. receives a Reduce rating with a composite score of 37.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.AXSM ranks #2,253 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Axsome Therapeutics, Inc. ranks #263 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

AXSM Stock Price and 52-Week Range

Axsome Therapeutics, Inc. (AXSM) currently trades at $178.11. The stock lost $0.79 (0.4%) in the most recent trading session. The 52-week high for AXSM is $191.50, which means the stock is currently trading -7.0% from its annual peak. The 52-week low is $86.99, putting the stock 104.7% above its annual trough. Recent trading volume was 560K shares, suggesting relatively thin trading activity.

Is AXSM Overvalued or Undervalued? — Valuation Analysis

Axsome Therapeutics, Inc. (AXSM) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 97.76x, versus the sector average of 2.75x. The price-to-sales ratio is 15.77x, compared to 1.66x for the average Healthcare stock.

At current multiples, Axsome Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Axsome Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Axsome Therapeutics, Inc. (AXSM) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -248.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -31.8% versus the sector average of -33.1%.

On a margin basis, Axsome Therapeutics, Inc. reports gross margins of 93.0%, compared to 71.5% for the sector. The operating margin is -39.5% (sector: -66.1%). Net profit margin stands at -42.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 96.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

AXSM Debt, Balance Sheet, and Financial Health

Axsome Therapeutics, Inc. has a debt-to-equity ratio of 681.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.55x, suggesting adequate working capital coverage. Total debt on the balance sheet is $202M. Cash and equivalents stand at $325M.

AXSM has a beta of 0.61, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Axsome Therapeutics, Inc. is 68/100, reflecting average volatility within the normal range for its sector.

Axsome Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Axsome Therapeutics, Inc. reported revenue of $547M and earnings per share (EPS) of $-3.68. Net income for the quarter was $-219M. Gross margin was 93.0%. Operating income came in at $-202M.

In FY 2025, Axsome Therapeutics, Inc. reported revenue of $638M and earnings per share (EPS) of $-3.68. Net income for the quarter was $-183M. Revenue grew 65.5% year-over-year compared to FY 2024. Operating income came in at $-167M.

In Q3 2025, Axsome Therapeutics, Inc. reported revenue of $171M and earnings per share (EPS) of $-0.94. Net income for the quarter was $-47M. Revenue grew 63.2% year-over-year compared to Q3 2024. Operating income came in at $-46M.

In Q2 2025, Axsome Therapeutics, Inc. reported revenue of $150M and earnings per share (EPS) of $-0.97. Net income for the quarter was $-48M. Revenue grew 72.1% year-over-year compared to Q2 2024. Operating income came in at $-37M.

Over the past 8 quarters, Axsome Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $87M to $547M. Investors analyzing AXSM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

AXSM Dividend Yield and Income Analysis

Axsome Therapeutics, Inc. (AXSM) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

AXSM Momentum and Technical Analysis Profile

Axsome Therapeutics, Inc. (AXSM) has a momentum factor score of 56/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 66/100 reflects moderate short selling activity.

AXSM vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Axsome Therapeutics, Inc. (AXSM) ranks #263 out of 838 stocks based on the Blank Capital composite score. This places AXSM in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing AXSM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full AXSM vs S&P 500 (SPY) comparison to assess how Axsome Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

AXSM Next Earnings Date

No upcoming earnings date has been announced for Axsome Therapeutics, Inc. (AXSM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy AXSM? — Investment Thesis Summary

The quantitative profile for Axsome Therapeutics, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Low volatility (stability score 68/100) reduces downside risk.

In summary, Axsome Therapeutics, Inc. (AXSM) earns a Reduce rating with a composite score of 37.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on AXSM stock.

Related Resources for AXSM Investors

Explore more research and tools: AXSM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare AXSM head-to-head with peers: AXSM vs AZN, AXSM vs SLGL, AXSM vs VMD.